Generate Biomedicines, Inc. (GENB)
Healthcare
Biotechnology
14.00 $
-0.2%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Generate Biomedicines, Inc. (GENB)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 47.0% of the shares are freely tradable; institutional investors hold 76.1%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
76.1%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
14.1%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
47.0%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
9.4%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
128Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Flagship Ventures Management, Inc. | 48.89 | 62,673,117 | +0.0 | 03/31/2026 |
| FMR Inc | 3.29 | 4,217,524 | +0.0 | 03/31/2026 |
| Capital World Investors | 3.12 | 4,004,149 | +0.0 | 03/31/2026 |
| BRAIDWELL LP | 2.80 | 3,592,999 | +0.0 | 03/31/2026 |
| JPMorgan Chase & Co | 2.30 | 2,947,259 | +0.0 | 03/31/2026 |
| T. Rowe Price Associates, Inc. | 1.65 | 2,109,633 | +0.0 | 03/31/2026 |
| ARCH VENTURE CORP | 1.52 | 1,944,426 | +0.0 | 03/31/2026 |
| Harbourvest Partners, LLC | 1.34 | 1,722,210 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| American Funds SMALLCAP World A | 2.93 | 3,752,630 | +2.8 | 06/30/2026 |
| T. Rowe Price Health Sciences | 1.39 | 1,787,637 | +0.0 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.